Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 13 08 2019
revised: 19 09 2019
accepted: 21 09 2019
pubmed: 23 10 2019
medline: 12 8 2020
entrez: 23 10 2019
Statut: ppublish

Résumé

Fragment-based screening by SPR enabled the discovery of chemical diverse fragment hits with millimolar binding affinities to the peptidyl-prolyl isomerase Cyclophilin D (CypD). The CypD protein crystal structures of 6 fragment hits provided the basis for subsequent medicinal chemistry optimization by fragment merging and linking yielding three different chemical series with either urea, oxalyl or amide linkers connecting millimolar fragments in the S1' and S2 pockets. We successfully improved the in vitro CypD potencies in the biochemical FP and PPIase assays and in the biophysical SPR binding assay from millimolar towards the low micromolar and submicromolar range by >1000-fold for some fragment derivatives. The initial SAR together with the protein crystal structures of our novel CypD inhibitors provide a suitable basis for further hit-to-lead optimization.

Identifiants

pubmed: 31635932
pii: S0960-894X(19)30675-4
doi: 10.1016/j.bmcl.2019.126717
pmc: PMC7195332
pii:
doi:

Substances chimiques

Enzyme Inhibitors 0
Lactams 0
Cyclophilins EC 5.2.1.-
PPID protein, human EC 5.2.1.8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126717

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Curr Top Med Chem. 2003;3(12):1392-409
pubmed: 12871171
Circ J. 2013;77(5):1111-22
pubmed: 23538482
Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1113-8
pubmed: 20026006
Viruses. 2012 Oct 29;4(11):2558-77
pubmed: 23202494
Nat Rev Drug Discov. 2014 Feb;13(2):105-21
pubmed: 24481311
J Chem Inf Model. 2011 Dec 27;51(12):3180-98
pubmed: 22087588
Gastroenterology. 2019 Nov;157(5):1368-1382
pubmed: 31336123
Anal Biochem. 2006 Sep 1;356(1):100-7
pubmed: 16737676
Front Biosci. 2004 Sep 01;9:2285-96
pubmed: 15353287
Acta Crystallogr D Biol Crystallogr. 2005 May;61(Pt 5):513-9
pubmed: 15858260
J Bioenerg Biomembr. 2005 Jun;37(3):121-8
pubmed: 16167169
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12037-42
pubmed: 12218175
J Med Chem. 2016 Mar 24;59(6):2596-611
pubmed: 26950392
PLoS Biol. 2010 Jul 27;8(7):e1000439
pubmed: 20676357
Nat Commun. 2016 Sep 22;7:12777
pubmed: 27652979
Drug Discov Today. 2007 Dec;12(23-24):1032-9
pubmed: 18061882
Science. 1984 Nov 2;226(4674):544-7
pubmed: 6238408
Genome Biol. 2005;6(7):226
pubmed: 15998457
J Med Chem. 2006 Feb 9;49(3):900-10
pubmed: 16451056
J Med Chem. 2009 Sep 10;52(17):5295-8
pubmed: 19691347

Auteurs

Ulrich Grädler (U)

Merck Healthcare, Merck KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany. Electronic address: ulrich.graedler@merckgroup.com.

Daniel Schwarz (D)

Merck Healthcare, Merck KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany.

Michael Blaesse (M)

Proteros Biostructures GmbH, Bunsenstraße 7a, D-82152 Planegg-Martinsried, Germany.

Birgitta Leuthner (B)

Merck Healthcare, Merck KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany.

Theresa L Johnson (TL)

Merck Healthcare, Merck KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany.

Frederic Bernard (F)

EMD Serono Research & Development Institute Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA.

Xuliang Jiang (X)

EMD Serono Research & Development Institute Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA.

Andreas Marx (A)

Merck Healthcare, Merck KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany.

Marine Gilardone (M)

Edelris, 115 Avenue, Lacassagne, F-69003 Lyon, France.

Hugues Lemoine (H)

Edelris, 115 Avenue, Lacassagne, F-69003 Lyon, France.

Didier Roche (D)

Edelris, 115 Avenue, Lacassagne, F-69003 Lyon, France.

Catherine Jorand-Lebrun (C)

EMD Serono Research & Development Institute Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH